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SUMMARY
Mammary epithelia are composed of luminal andmyoepithelial/basal cells whose neoplastic transformations
lead to distinct types of breast cancers with diverse clinical features. We report that mice deficient for the
CDK4/6 inhibitor p18Ink4c spontaneously developER-positive luminal tumors at a high penetrance. Ink4cdele-
tion stimulates luminal progenitor cell proliferation atpubertal ageandmaintains anexpanded luminal progen-
itor cell population throughout life.Wedemonstrate thatGATA3binds toand represses INK4C transcription. In
humanbreast cancers, low INK4C andhighGATA3 expressions are simultaneously observed in luminal A type
tumors andpredict a favorablepatient outcome.Hence, p18INK4C is adownstream target ofGATA3, constrains
luminal progenitor cell expansion, and suppresses luminal tumorigenesis in the mammary gland.INTRODUCTION
Mammary epithelia are composed of two major epithelial cell
types: ductal and alveolar luminal cells, constituting the inner
layer of ducts and the lobuloalveolar units, respectively; and
a basal layer of myoepithelial cells surrounding the luminal cells.
Both epithelial cell types are believed to originate from a common
multipotential stem cell (Shackleton et al., 2006; Stingl et al.,
2006). Histopathologically, breast cancer can be divided into
two major types: luminal tumors that account for the majority
of breast cancer cases (70%–80%) and are typically estrogen
receptor (ER) positive; and basal-like breast cancers that have
high histological grades and mitotic indices, are ER negative,
and are associated with a poor prognosis (Althuis et al., 2004).Gene expression profiling analyses have further categorized
human breast tumors into several intrinsic subtypes that corre-
late with tumor biology and are prognostic and predictive for
patient outcomes (Hu et al., 2006; Perou et al., 2000; Sorlie
et al., 2003). The genetic, cellular, and biochemical mechanisms
controlling lineage commitment and maturation in the mammary
gland bear clinical significance, because different types of breast
tumors possess different outcomes and are diverse in their
responsiveness to treatment but remain to be defined. The
cellular origin of breast cancer and how its various subtypes arise
are not fully understood, and appropriate animal models for
studying this disease are still needed.
p18Ink4c (referred to as p18 hereafter) is a member of the
mammalian INK4 family that inhibits CDK4 and CDK6, whoseSIGNIFICANCE
Breast cancer is heterogenous with tumors pathologically distinct and diverse in their responsiveness to treatment. We
show that the CDK inhibitor p18INK4c gene is repressed by GATA3, a transcription factor specifying mammary luminal
cell fate, and that low INK4C and highGATA3 expressions are associated with human luminal A type tumors and with better
patient survival. p18Ink4c-null mice have an expanded luminal progenitors at a young age and throughout life and develop
ER+ luminal tumors at high penetrance. These results identify the escape of luminal progenitors from quiescence as
a rate-limiting step for initiation of mammary luminal tumors. The Ink4c-null mouse represents a unique model for study
and for developing therapeutic strategies to treat luminal tumors.Cancer Cell 15, 389–401, May 5, 2009 ª2009 Elsevier Inc. 389
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A Mouse Model for ER+ Luminal Breast Canceractivation by mitogen-induced D-type cyclins leads to phosphor-
ylation and functional inactivation of RB, p107, and p130.
Functional inactivation of this pathway is a common event in
the development of most types of cancer (Sherr, 1996). p18 is
a haploinsufficient tumor suppressor in mice whose deletion pro-
motes the development of various tumors, including lymphoma,
medulloblastoma, glioblastoma, and tumors of neuroendocrine
organs, lung, and prostate (Bai et al., 2003, 2006; Franklin et al.,
1998; Latres et al., 2000; Pei et al., 2007; Uziel et al., 2005). Dele-
tion or reduced expression of the p18 gene has also been
observed at high frequency in different types of human cancer.
Three lines of evidence suggest a potential function of p18 in
suppressing mammary tumors. First, the cyclin D1 gene, located
on human chromosome 11q13 and a functional antagonist of
Figure 1. p18-Null Mice Develop Spontaneous
Luminal Mammary Tumors
(A) Mammary tumor-free survival of Balb/c mice of
different genotypes.
(B) Spontaneous tumor development in Balb/c-p18
mutant mice.
(C) Representative H&E staining of primary mammary
tumor (T) and lung metastasis (M) developed in p18/
mice. A WT mammary control at a similar age is shown.
(D) Immunofluorescent staining of CK5 and CK8 in age-
matched (14–16 months of age) mammary tissue from
WT mice or tumors from mutant mice. The patched green
signals inside the WT glands are autofluorescence caused
by the secretion of milk.
(E) Immunohistochemical staining of ERa (brown) in
mammary tumors from p18/ mice. Note the highly ex-
pressed ERa levels in normal mammary glands (arrows)
surrounding tumors. Boxed areas are magnified in the
insets.
p18, is amplified in a substantial portion of
human breast cancer (reviewed in Ormandy
et al., 2003). Transgenic expression of MMTV
(mouse mammary tumor virus) cyclin D1
promotes mammary tumor development
(Wang et al., 1994). Second, deletion in mice
of cyclin D1 or CDK4, the target of p18,
conversely retards mammary gland develop-
ment and prevents MMTV-oncogene induced
mammary cancer (Fantl et al., 1995; Sicinski
et al., 1995; Yu et al., 2001, 2006). Lastly, female
p18 null mice (in BL/6 background) display
mammary gland hyperplasia with ectasia in their
galactophor ducts (Latres et al., 2000 and our
unpublished observation). We carried out this
study to determine the function and mechanism
of p18 in suppressing mammary tumorigenesis.
RESULTS
p18/ Mice Develop Predominantly
ERa-Positive Luminal Mammary Tumors
To determine the function of p18 in mammary
tumor suppression, we introduced p18/ into
the Balb/c strain, which is known to be suscep-
tible to mammary tumor development and is widely used for such
study, by backcross (Ponnaiya et al., 1997; Ullrich et al., 1996).
The tumor spectrum, incidence, and onset time of many tissues,
including pituitary, thyroid, testis, pancreas, and lung, increased
in the Balb/c background compared with the BL/6 background
(data not shown). The most striking phenotype in Balb/c-p18
mice was mammary gland tumors, and mammary tumor-free
survival was reduced from a mean age of 27.3 months in wild-
type (WT) mice, to 20.9 months in p18+/ and 15.4 months in
p18/ mice (Figure 1A).
Mammary tumors developed in Balb/c-p18/ mice at a very
high incidence, including 23% (n = 13) of females examined
less than 1 year of age and 88% (n = 17, including 1 male)
between 1 year and 20 months (Figure 1B). Most mammary390 Cancer Cell 15, 389–401, May 5, 2009 ª2009 Elsevier Inc.
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A Mouse Model for ER+ Luminal Breast CancerFigure 2. Increased Cell Proliferation and Rb Protein Phosphorylation in p18/ Mammary Epithelium and Tumors
(A) Immunostaining of Ki67 (brown) of 18-month-old virgin p18+/ and p18/ mammary glands.
(B) Immunostaining of BrdU (green), CK8 (red), and DAPI (blue) in mammary glands of 9-month-old virgin littermate mice. The boxed areas were enlarged in the
insets to show BrdU incorporation (pointed by white arrows) in an individual gland. The percentages of BrdU-positive cells were calculated from cells situated in
clear duct/gland structure. Results represent the mean and standard deviation (±SD) of three animals per group.
(C) Immunostaining of BrdU (green) in mammary glands of 8-week-old virgin littermate mice was performed to determine cell proliferation and nuclei were stained
with DAPI (blue). The percentages of BrdU-positive cells were calculated from cells situated in clear duct/gland structure. Results represent the mean ± SD of
three animals per group.
(D) Sections of normal mammary glands and mammary tumors of WT and p18/mice at around 1 year of age were examined for pRb protein phosphorylation at
Ser608 by CDK4 and CDK6. Counterstaining is blue and positive staining is brown. The percentages of pRb-S608-positive cells were calculated from cells
situated in clear duct/gland structure in normal glands and from all cells in tumors. Results represent the mean ± SD of three animals per group.tumors from p18/ and p18+/ mice were preinvasive carci-
nomas, such as ductal carcinoma in situ (DCIS), and exhibited
papillary, cribriform, and cystic characteristics with low and
intermediate nuclear grades (Figure 1C). Only 2 of 18 (11%)
p18/ mammary tumors were invasive ductal carcinoma
(IDC), and one of them metastasized to the lung.
Normal breast ducts contain two types of epithelial cells:
luminal cells that are round or polygonal and line the inner ductal
lumen, and basal/myoepithelial cells that are elongated and
contact the basement membrane but never contact the lumen.
Luminal and basal/myoepithelial cells can also be distinguished
by their different cytokeratin (CK) expression patterns. The
majority of luminal cells express CK7, 8, 18, 19, and 20, whereas
basal/myoepithelial cells typically express CK5, 13, 14, and 17.
p18/ mammary carcinomas, most of which retained an orga-
nized gland and duct structure, stained strongly and uniformly
for CK8 but not CK5, indicating that they predominantly contain
luminal epithelial cells (Figure 1D).
Most (13 of 15, 87%) p18/mammary tumors examined were
positive for ERa. The percentages of ERa-positive cells varied
among individual p18/ mammary tumors, from as low as
2%–5% in six tumors, to more than 20% in the other nine, indi-
cating heterogeneity and potentially different stages of tumordevelopment. ERa-positive cells were frequently detected in
p18/ mammary tumors, where tumors were well differentiated
and still retained an overall normal architecture of mammary
glands (Figure 1E, left and middle), or when poorly differentiated
tumors were investigated (Figure 1E, right). When compared with
13 different murine mammary tumor models (Herschkowitz et al.,
2007), p18/ mammary tumors express the highest level of ER
(data not shown). It should be pointed out, however, that most
mammary tumors developed in p18/ mice are DCIS, with
only 11% IDC or metastatic tumors, whereas mammary tumors
developed in other murine models are mostly invasive carci-
noma. It remains to be determined whether the difference in
ER expression between p18/ tumors and tumors of 13 other
models reflects different stages in tumor progression or inherent
differences in tumor biology. Together, these results suggest
that p18 plays an important role to suppress the development
of ERa-positive luminal mammary tumors in mice.
p18 Deficiency Stimulates Proliferation and Rb Protein
Phosphorylation in Luminal Cells
We determined cell proliferation in mammary tumors developed
in p18/ mice (>14 months of age) by examining both the pro-
liferation marker Ki67 (Figure 2A) and the mitotic markerCancer Cell 15, 389–401, May 5, 2009 ª2009 Elsevier Inc. 391
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A Mouse Model for ER+ Luminal Breast Cancerphosphorylated histone H3 (data not shown). Both analyses re-
vealed that there was active cell proliferation in p18/mammary
tumors compared with mammary tissues derived from age-
matched p18+/ or WT mice. As determined microscopically
by their inner localization in the mammary glands, a majority of
proliferating cells in p18/ mammary tumors were luminal cells.
We then determined mammary epithelial proliferation by pulse-
labeling 9-month-old virgin littermate WT and p18/ mice with
BrdU. At this age, most p18/ mammaries exhibit either normal
appearance or hyperplasia, and retain relatively normal architec-
ture of mammary glands but have not yet developed tumors.
There was very little cell proliferation in WT ductal epithelium,
and as expected, BrdU incorporation was barely detectable
(Figure 2B; note that green fluorescence outside the glands
does not correspond to individual cells and was likely caused
by nonspecific staining). In contrast, BrdU-positive cells in litter-
mate p18/ ductal epithelium were substantially increased.
Microscopic examination of four independent mammary glands
from three different mice of each genotype revealed a 3.8-fold
increase of BrdU-positive cells in p18/ mammary glands
(6.4% ± 2.3%) than in WT glands (1.7% ± 0.7%, Figure 2B).
Most p18/ ducts/glands contained more than two BrdU+ cells,
and nearly all BrdU+ cells were also positive to CK8 staining, indi-
cating that the majority of BrdU+ cells were luminal epithelia. Only
a few BrdU-positive cells coexpressed CK5, a marker for myoe-
pithelial cells (data not shown).
At 8 weeks of age, mammary ducts branch with active epithe-
lial cell proliferation, including both luminal and myoepithelial
cells, and no lesions were detected in p18/ mammaries as
confirmed by parallel hematoxylin and eosin (H&E) staining
(data not shown). p18 deficiency resulted in a 2.5-fold increase
of BrdU-positive cells in mammary epithelium, most of which
were luminal-like epithelial cells (Figure 2C). Finally, we directly
examined the status of Ser608 phosphorylation of Rb protein,
the site that is preferentially phosphorylated by p18’s targets
CDK4 and CDK6 (Schmitz et al., 2004; Zarkowska et al., 1997).
A visible and consistent increase of pRb-Ser608 phosphoryla-
tion, both in the intensity and number of positive cells, was
seen in normal p18/ mammary epithelia (11.2 ± 1.8% in WT
to 23.5 ± 3.8% in p18/) and p18/ tumors (34.5 ± 5.7%,
Figure 2D), supporting the activation of CDK4 and/or CDK6.
Most Rb-Ser608-positive cells were luminal cells. Taken
together, these results demonstrate that p18 deficiency stimu-
lates CDK4 and/or CDK6 activity toward the Rb protein in luminal
epithelial cells, increasing their proliferation in a cell autonomous
manner at an early age before the development of any detectable
preneoplastic lesion. Loss of p18 also maintains luminal cells at
a hyperproliferative state throughout adulthood, during which
time p18/ luminal cells progressively develop from hyperplasia
to tumor.
Loss of p18 Increases Label-Retaining Luminal
Epithelial Cells
We explored the possibility that p18 loss stimulates mammary
stem and/or luminal progenitor cell proliferation. One unique
feature of stem/progenitor cells is their slow rate of proliferation.
As a result, the BrdU label incorporated during a long period of
pulse labeling can be retained after a long period of chase by
the stem/progenitor cells but is continuously diluted in other392 Cancer Cell 15, 389–401, May 5, 2009 ª2009 Elsevier Inc.somatic cells by each cell cycle. Label-retaining cells (LRCs)
have been demonstrated to be enriched in both mammary
stem and progenitor cells (Shackleton et al., 2006; Smith, 2005;
Welm et al., 2002). We injected BrdU into pubertal littermates
twice a day consecutively for 7 days and determined the LRCs
after short (1 day) and long (37 days) chase. At day 1 of chase,
more than half of the epithelial cells were BrdU positive in both
WT (51.7% ± 6.8%) and p18/ mammaries (55.3% ± 8.1%)
(Figure 3A). After 37 days of chase, BrdU-positive LRCs were
only sparsely detected in the WT mammaries but were notably
increased in p18/ mammaries (Figure 3B). Microscopic exam-
ination of 12 mammary glands from three mice of each genotype
revealed a 1.6-fold increase of LRCs in p18/ mammary glands
(14.5% ± 1.8%) over WT glands (9.1% ± 1.3%).
Most LRCs in both WT and p18/ mammaries were round or
polygonal, located in the inner layer of the duct, and made
contact with the ductal lumen, indicative of luminal epithelium.
To confirm this, we stained mammary sections with CK8 and
CK5 and determined that, indeed, most WT (7.3% ± 1.4% of total
mammary epithelium and 80.2% of total LRC) and p18/ LRCs
(12.04% ± 1.7% of total mammary epithelium and 83% of total
LRC) were positive for CK8 (Figure 3B). Notably, the CK8-posi-
tive LRCs, which are likely enriched for luminal progenitor cells,
were increased by 1.7-fold by p18 loss, from 7.3% of total
epithelial cells in WT mammaries to 12% in p18/ mammaries
(Figure 3B).
Loss of p18 Increases Cells with Morphologic Features
of Luminal Progenitors
Previously, Smith and colleagues combined light and electronic
microscopic analyses of the mammaries from different
mammals and defined five histologically distinct epithelial cell
populations based on the cell size and nuclear and cytoplasmic
staining characteristics: small light cell (SLC), undifferentiated
large light cell (ULLC), differentiated large light cell (DLLC), large
dark cell (LDC), and myoepithelial cell (MYO) (Chepko et al.,
2005; Smith and Medina, 1988). Both small and large light cells
appear to be division competent, based on their condensed
chromosomes and capability to undergo mitosis in explant
culture. Combined with the characterization of the cytoplasmic
organelle differentiation and localization in the glands, these
features led to the proposal that SLCs represent a population
enriched for mammary stem cells that divide and differentiate
progressively into ULLC, likely corresponding to the luminal
progenitors, and then to DLLC, before terminal differentiation
into a bulk population of mature luminal cells (LDCs).
To determine the division competency of these structurally
defined cell populations and their label-retaining ability, we
took immunostained sections from the label retaining assay
(37 day chase), restained them with H&E, and matched 793 cells
from WT and 946 cells from p18/ mammaries from two stain-
ings by side-by-side microscopic comparison (Figure 3C and
Table S1 available online). Of these matched cells, 70 from WT
and 150 from p18/ mammaries were LRCs, and close to half
(44% in WT and 48% in p18/ mammary, respectively) corre-
sponded to ULLCs. The remaining LRCs were similarly distrib-
uted among SLCs, DLLCs, LDCs, and MYOs (Table S1). This
result indicates that ULLCs represent the majority of LRCs,
providing functional support to the histologically defined notion
Cancer Cell
A Mouse Model for ER+ Luminal Breast CancerFigure 3. Loss of p18 Increases Label-Retaining Luminal Epithelial Cells and Cells with Morphologic Features of Luminal Progenitors
(A and B) One-month-old littermate mice were injected intraperitoneally with BrdU twice a day for 7 consecutive days, followed by chase for 1 (A) or 37 days (B)
before death. Mammaries were dissected and stained with antibodies to BrdU, CK5, and CK8. The percentage of BrdU-positive cells were calculated as
described in Experimental Procedures. Results represent the mean ± SD of three animals per group.
(C) After immunofluorescence staining and photographing of sections from the label retaining assay (37 days chase, top panels), the identical section was
restained with H&E. Matched cells between two stainings were identified microscopically and label-retaining small light cells (SLCs) and undifferentiated large
light cells (ULLCs) were counted (indicated by red and yellow arrows, respectively, bottom panels). Lower-magnification pictures for these paired stainings are
shown in (B). Three additional types of histological distinct cell types—differentiated large light cells (DLLCs), large dark cells (LDCs), and myoepithelial cells
(MYOs)—were also identified and quantified (see Table S1).
(D) Littermate WT or p18/ mice at 2–3 months of age were dissected and stained with H&E. SLCs and ULLCs are indicated by red and yellow arrows, respec-
tively. A total of 400–600 ductal and lobular cells from each genotype were counted, and the number and percentage of SLCs and ULLCs are presented. Three
other histological types (DLLCs, LDCs, and MYOs) were also identified and quantified (Figure S1).that ULLCs represent a progenitor-enriched mammary epithelial
cell population.
We next microscopically examined more than 20 ducts and
lobules from each animal of both genotypes between 2 and
3 months of age, and counted at least three lobules and one
duct per animal (Figure S1). Of five major populations, the ULLC
population was significantly increased from 16.5% in ducts and
19% in lobules of WT mammaries, to 28.1% and 25% in p18/
ducts and lobules, respectively, and led to a 50% overall increase
of ULLCs from WT (17.6%) to p18/ (26.5%) mammaries
(Figure 3D, and Figure S1). The SLC population was very small
(less than 3%) and partially overlapped with myoepithelial cells
in their localization, making it difficult to determine whether p18
deletion also affects the size of the putative mammary stem cell
population. There is no significant difference in relative distribu-
tion of the other three populations, as well as cells of unknown
(UK) origin, between WT and p18/ mammaries (Figure S1).
These results demonstrate that luminal progenitor-enriched
ULLCs are the major cell population affected by the loss of p18
at an early age, before tumor development.p18 Deficiency Expands and Maintains the Luminal
Progenitor-Enriched Cell Population
To corroborate the finding that loss of p18 expands luminal
progenitor cells, we dissected mammary glands from 6–8-week-
old mice and analyzed them by flow cytometry. After exclusion
of lymphocytes (SSC low), dead cells (7AAD positive), hematopoi-
etic cells (CD45+TER119+), and endothelial cells (CD31+), the
expression profile for CD24 and CD29 was determined
(Figure S2A). The CD29loCD24+ population, which is enriched
with progenitors and has a luminal cell fate under lactogenic
condition (Asselin-Labat et al., 2007; Shackleton et al., 2006; Slee-
man et al., 2007), was increased by 1.5-fold inp18/mammaries
compared with WT littermates in Balb/C (42.3 ± 2.5% versus
27.9 ± 3.7%, Figure 4A) and 1.4-fold in BL/6 (51% versus
35.9%, Figure S2B) backgrounds at pubertal age (6–8 weeks).
The CD29loCD24+ cells were very similar between p16/ and
p16+/mice (26.52% versus 25.83%, data not shown), supporting
a specific role of p18 in controlling luminal progenitor cell prolifer-
ation in pubertal mice. The CD29loCD24+ cell population was simi-
larly increased in postpubertal (10–12 weeks) p18/ mammariesCancer Cell 15, 389–401, May 5, 2009 ª2009 Elsevier Inc. 393
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A Mouse Model for ER+ Luminal Breast CancerFigure 4. p18 Loss Expands Luminal Progenitors
(A–D) Mammary cells from WT (or p18+/) and p18/ virgin littermate mice of Balb/c backgrounds at indicated ages were isolated, sorted, and analyzed by flow
cytometry for CD24 together with CD29 (A), CD49f (B), SCA1 (C), or Ki67 (D). The bar graphs in (A) represent the mean ± SD of three animals per group.(42.7 ± 4.0% versus 34.1 ± 2.6%, Figure 4A), and remained high
late in life in p18/ mice, 48.3% at 9 months of age and 37.8%
(in hyperplasic tissues) or 42.1% (in tumorigenic tissues) at
14 months of age, and both were higher than WT littermates
(41% and 34% at 9 and 14 months of age, respectively). These
data suggest that p18 loss results in a continuous increase in
the luminal progenitor-enriched CD29loCD24+ cell population
during aging and development.
CD49f (a6 integrin) is expressed in human mammary colony-
forming cells (Ma-CFC) enriched for luminal progenitor cells
and has also been used in combination with CD24 to identify
mouse Ma-CFCs and stem cells (Stingl et al., 2001, 2006). After
exclusion of lymphocytes and dead, hematopoietic, and endo-
thelial cells, we determined that the CD24highCD49flow population
was significantly increased in p18/mammaries compared with
WT littermates by 1.8-fold in Balb/c (6 weeks, 7.9% versus 4.2%,
Figure 4B) and 1.7-fold in BL6 (12 weeks, 6.6% versus 3.8%,
Figure S2D) backgrounds. The CD24highCD49fhigh population
enriched for mammary stem cells, however, did not appear to be
significantly affected by p18 loss (3.6% versus 3.2%, Figure 4B).394 Cancer Cell 15, 389–401, May 5, 2009 ª2009 Elsevier Inc.The CD24highCD49flow population in p18/ mammary mice also
remained higher at 11 months of age than in WT littermate
mammaries (5.5% versus 4.0%, Figure S2E). These results
further support the function of p18 in constraining luminal
progenitor expansion.
CD24+ mammary epithelial cells are enriched for luminal cells
and can be further separated into two distinct populations based
on the expression of either Sca1 or prominin-1, which almost
completely overlap: a CD24+Sca1 or CD24+prominin-1 popu-
lation that is enriched (>40%) for colony-forming cells (i.e.,
luminal progenitor cells); and a CD24+Sca1+ or CD24+prominin-
1+ population that is enriched (>80%) for cells expressing genes
involved in sensing systemic hormones such as ERa, proges-
terone receptor, and prolactin receptor and contains little stem
cell activity (Sleeman et al., 2006, 2007). Consistent with the
expansion of the CD29loCD24+ cell population, the CD24+Sca1
population was also higher in p18/ mice than in littermate WT
mice at postpubertal age (28.3% versus23.3%) and maintained
at a higher level later in life (59% in p18/ versus 50% in WT
mice at 9 months of age and 57% in p18/ versus 41.7% in
Cancer Cell
A Mouse Model for ER+ Luminal Breast Cancerp18+/ mice at 14.5 months of age) (Figure 4C). Similar results,
that p18 deficiency increased both CD24+Sca1 (14% versus
9%) and CD24+Sca1+ populations (39% versus 25%) when
compared with WT littermates, were also obtained in BL/6 mice
(Figure S2C), indicating that the function of p18 in constraining
luminal cells is not strain dependent.
To directly demonstrate that the proliferation of luminal
progenitor cell populations is increased in p18/ pubertal
mice, we isolated mammary epithelial cells and stained them
with CD24 and intracellularly with the proliferation marker Ki67
after depletion for lymphocytes and Lin+ cells. The CD24+Ki67high
population was increased from 29.3% in WT mammaries to
43.1% in p18/ mammaries (Figure 4D), providing further
evidence that p18 loss initiates the expansion of a luminal
progenitor-enriched cell population.
p18 Constrains Luminal Progenitor Cell Proliferation
in a Cell Autonomous Manner
We next determined the function of p18 in constraining luminal
progenitor cell proliferation using three different in vitro systems:
3D Matrigel, mammosphere, and colony-formation assays. The
Matrigel assay showed that mammary cells derived from p18/
mice exhibited a substantial increase of proliferation and that the
majority of BrdU-positive cells were luminal (Figure 5A), demon-
strating that the increased proliferation of luminal cells in p18/
mice is cell autonomous. Mammary stem/progenitors propa-
gated in nonadherent culture in vitro form mammospheres and
can differentiate into both luminal and basal/myoepithelial line-
ages (Dontu et al., 2003). Cells derived from p18/ mammaries
showed an increase in primary mammosphere-forming activity
(32.8 ± 5.1 spheres per 20,000 cells) than WT cells (26.3 ± 3.4
spheres per 20,000 cells; p = 0.027, paired t test, Figure 5B), indi-
cating increased stem or progenitor cell function resulting from
p18 loss. Most WT spheres were 70–100 mm and 10%–20%
were larger than 100 mm, whereas most p18/ spheres were
80–120 mm in size and 10%–20% spheres were larger than
120 mm (Figure 5B). The average p18/ sphere (118 ± 38 mm)
was significantly larger than the average WT sphere (92 ± 24 mm,
p = 0.017, paired t test, Figure 5B), further supporting the
conclusion that p18 loss increases the proliferative potential of
mammary progenitor cells. To examine their differentiation
potential, we induced individual mammospheres to differentiate.
After 4 days of culture in a gelatin-coated dish, most cells in the
spheres were attached, differentiated, and migrated out of the
center. Immunostaining identified CK8+ and CK5+ cells in both
WT and p18/ spheres (Figure S3), confirming that the spheres
were capable of differentiating into both luminal and basal/
myoepithelial lineages and that p18 deficiency did not affect
the differentiation potential of the mammosphere.
We then compared the colony-forming capacity of WT and
p18/ mammary epithelial cells (MECs) in Matrigel and scored
both spherical and flat colonies. To score spherical colonies, we
divided them into > 50 mm and > 100 mm groups and found that
p18/ MECs formed more spherical colonies in both groups,
averaging 10.8 colonies > 100 mm or 9.5 colonies > 50 mm per
1000 MECs seeded, compared with WT or heterozygous
MECs that formed on average 6.8 colonies > 100 mm or 4.5 colo-
nies > 50 mm per 1,000 MECs seeded (Figure 5C). The p18/
MECs also appeared to form more flat colonies in both sizegroups, but the limited number of flat colonies formed by both
WT and p18/ MECs prevented us from making a statistically
significant determination (Figure 5C). Because we used MECs
in these FACS and colony-formation assays, we cannot exclude
the possibility that p18 might also have a function in regulating
stroma cells in vivo, which could contribute to the control of
luminal progenitor cell expansion. Almost all spherical colonies
generated from either WT or p18/ MECs, including both acini
with or without lumen, stained strongly for CK8, with varying
degrees of CK5 staining (Figure S4A). Staining of colonies after
dissolving Matrigel revealed two distinct groups of colonies: one
containing cells in the center that were strongly stained for CK8
and a few outer layer cells that were stained positively for
CK5 (Figure S4B, left panels); and one comprised uniformly of
CK8+ cells throughout the colony (right panels).
To obtain a quantitative assessment, we generated more colo-
nies by seeding a high density of unsorted mammary cells on
Matrigel (20-fold more than clonal density). Flat colonies were
difficult to identify accurately due to their high density and
were not counted. p18/ mammary cells formed significantly
more spherical colonies in both > 50 mm and > 100 mm size
groups and slightly more colonies larger than 200 mm compared
with WT littermate mammary cells (Figure S4C). Most spherical
colonies stained strongly for CK8 with varying degrees of CK5
staining. Considering that serum-free culture conditions favor
luminal cell proliferation, which might cause an underestimation
of the myoepithelial cells, we divided the spherical colonies into
two groups: ‘‘basal colonies’’ (CK8+ and > 50% CK5+ cells) and
‘‘luminal colonies’’ (CK8+ and < 50% CK5+ cells) (Figure 5D).
Microscopic examination demonstrated that p18/ mammary
cells generated 1.6-fold more luminal colonies (377 ± 50.3 per
20,000 cell seeded) than did WT mammary cells (232 ± 30.1
per 20,000 cell seeded, Figure 5D). p18/ mammary cells
generated slightly more CK5+ cell enriched basal-like colonies
(104 ± 14.7 per 20,000 cells seeded) than the WT MECs (87 ±
17.3 per 20,000 cells seeded), but the increase was not statisti-
cally significant (p = 0.27, Figure 5D). This result supports
a unique function of p18 in luminal progenitor proliferation and
differentiation.
p18 andGATA3 Expression Levels Are Inversely Related
in Human Luminal A Breast Tumors
To determine whether our mouse genetic analysis models human
breast cancers, we queried the gene expression data of the
Netherlands Cancer Institute 295 (NKI295) breast cancer patient
sample set (van de Vijver et al., 2002). The 295 patients were split
50/50 into a ‘‘high’’ and ‘‘low’’ expression group for each
analyzed gene and the distribution of ‘high’ versus ‘low’ expres-
sion of each gene was determined relative to five intrinsic tumor
subtypes: basal-like, Her2+/ERa, luminal A, luminal B, and
normal-like as assigned (Fan et al., 2006). Using multiple statis-
tical tests, we determined that p18 mRNA expression levels
were highly correlated with the breast tumor intrinsic subtype
(chi-square p < 0.0001; Figure 6A and Table S2). Notably, p18
and p19 INK4D (data not shown) levels, but not five other CDK
inhibitor genes, tended to be low in the Luminal A subtype of
human breast cancers (p = 0.003), which are almost exclusively
ERa+ and high in basal-like tumors (p < 0.0001). These results
are consistent with the finding that mammary tumors developedCancer Cell 15, 389–401, May 5, 2009 ª2009 Elsevier Inc. 395
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(A) Mammary cells freshly isolated from both WT and p18/ mice were cultured in 3D Matrigel for 1 week, pulse labeled with BrdU, and acini were stained for
antibodies to CK8 (red) and to BrdU (green). Two sections from two separate acini are shown.
(B) Mammary cells from WT and p18/ virgin littermate mice at 2–3 months of age were isolated and analyzed by mammosphere assay. Representative mammo-
spheres in common size (left panel) and in large size (right panel) are shown. The sphere size was measured as described in Supplemental Experimental Proce-
dures, and the number of spheres larger than 60 mm was quantified. The assay was performed in triplicate for each animal. The bar graphs represent the
mean ± SD of four animals per group.
(C) Freshly isolated mammary cells were plated in Matrigel-coated 24-well plate (1000 cells per well). Nine days after culture, colonies were photographed and
counted. Representative spherical and flat colonies are shown. The assay was performed in triplicate for each animal. The bar graphs represent the mean ± SD of
three animals per group.
(D) Freshly isolated mammary cells were plated in Matrigel-coated 24-well plates (20,000 cells per well). Nine days after culture, colonies were stained with CK8
and CK5 on Matrigel and counted as described in Supplemental Experimental Procedures. Representative luminal (red arrows) and myoepithelial colonies (green
arrows) are indicated. The assay was performed in triplicate for each animal. The bar graphs represent the mean ± SD of three animals per group.in p18/mice are predominantly comprised of luminal cells and
are ERapositive. Interestingly,RB1expression is low in basal-like
tumors (p = 0.0001) and high in luminal A tumors (p = 0.0008)
(Figure 6A and Table S2). An inverse correlation between p18396 Cancer Cell 15, 389–401, May 5, 2009 ª2009 Elsevier Inc.andRB1expression is consistent with the notion thatp18, among
four INK4 genes, is the major upstream activator of RB1, and its
decrease might relieve selection pressure to decrease or mutate
RB1 during tumorigenesis in mammary luminal cells.
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A Mouse Model for ER+ Luminal Breast CancerFigure 6. p18 and GATA3 Level Is Inversely Related to Luminal A Type Tumors and Conversely Predicts Human Breast Cancer Patient
Outcomes
(A) ANOVA and box plot analysis of gene expression levels in 295 breast cancer patients from the NKI patient series (Chang et al., 2005; van de Vijver et al., 2002)
according to tumor subtype.
(B) Scatter plot analysis of INK4C and GATA3 expression for 295 patients from the NKI patient series. Correlation coefficient (r) = 0.379, p value < 0.0001.
(C) A total of 295 patients from the NKI patient series were divided into high and low groups based on each gene’s rank order expression values. Probabilities for
overall survival are shown for each gene and the p values calculated.GATA3, a member of the GATA family of zinc-finger transcrip-
tional factors, was recently identified as essential for the differen-
tiation and maintenance of luminal cell fate and thus for
mammary-gland morphogenesis. Restoration of GATA3 in late
carcinomas from MMTV-PyMT mice induced tumor differentia-
tion and suppressed tumor dissemination (Kouros-Mehr et al.,
2008). Conspicuously, the expression ofGATA3 is high in luminal
A and low to absent in basal-like tumors, thus exhibiting an
inverse correlation with p18 (Figure 6A and Table S2). Scatter
plot analysis further confirmed the inverse correlation between
GATA3 and p18 mRNA levels in breast cancer patients from the
NKI patient series (correlation coefficient = 0.379, Figure 6B).
This finding suggests the possibility of negative regulation of
p18 by GATA3 (see below).
p18 and GATA3 Expression Levels Predict Human
Breast Cancer Patient Outcomes
We next examined whether the levels of p18 expression are
related to patient outcomes and included all CDK inhibitor genes
in the analysis to explore the specificity. Kaplan-Meier analysis of
overall survival revealed that ‘‘high’’ versus ‘‘low’’ expression of
p18INK4C, p19INK4D, and RB1 genes, but not p21CIP1/WAF1,
p27KIP1, p57KIP2, or p16INK4A, was significantly predictive of
patient outcome. High INK4C and INK4D expression and lowRB1 expression predicted poor patient outcome (Figure 6C).
Identical results were obtained for relapse-free survival
(Figure S5). The statistically significant value of p18 levels in pre-
dicting patient outcome is consistent with, and can be explained
by, the correlation between low p18 expression and luminal A
subtype tumors exhibiting a better outcome (Hu et al., 2006).
The profiling analyses linking the expression of INK4 and RB1
genes with patient outcomes also suggest how an impairment
of the RB pathway might clinically predict, and mechanically
influence, patient outcomes. A reduction of RB1 level, among
all genes acting on the RB pathway, would be most direct and
effective in diminishing the activity of the RB pathway and
promoting cell proliferation, and is therefore linked with, or leads
to, a more malignant phenotype (i.e., basal-like tumors), whereas
a reduction of its individual upstream activators, such as
p18INK4C, is less potent in promoting cell division and is linked
with less aggressive tumors (luminal A tumors). Notably, contrary
to p18 expression, high GATA3 expression predicts a better
patient outcome, thus showing that human luminal A tumors
are characterized by high GATA3, high RB1, and low p18.
GATA-3 Negatively Regulates p18 Gene Expression
Prompted by the inverse correlation between p18 and GATA3
expression in human luminal A breast cancer patients, and theCancer Cell 15, 389–401, May 5, 2009 ª2009 Elsevier Inc. 397
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A Mouse Model for ER+ Luminal Breast CancerFigure 7. p18 Is a Direct Target of GATA3 in Mammary Epithelium
(A) Mammary cells from WT mice at 7 weeks of age were isolated and sorted by flow cytometry for CD24 and CD29 cell populations. Total RNA from the indicated
cell populations (R4, CD24CD29, R3, CD24+CD29, R2, CD24+CD29+) was extracted and analyzed for the expression of Gata3 and p18 by quantitative real-
time polymerase chain reaction (Q-RT-PCR). Data are expressed relative to the corresponding values for R4 populations as mean ± SD from triplicates of each of
the two independent mice.
(B) Mammary tissues from Gata3f/f;WAP-cre+ and Gata3f/f;WAP-cre dams that successfully produced and nursed pups were analyzed for Gata3 and p18
expression. Mammary tissues from 2-month old virgin WT and p18-null females were used as control. n.s., nonspecific bands.
(C and D) Human MCF-7 or 293T cells were transfected with either scrambled siRNA (Ctrl) or siRNA targetingGATA3, and the cells were lysed for western blot, (C)
or the RNA were extracted for Q-RT-PCR (D) 48 hr after transfection. Similar results were derived from two different siRNA targeting different sequences of
GATA3. Data are expressed relative to the corresponding values for control (Ctrl) cells as mean ± SD from triplicates of a representative experiment.
(E) MCF-10A cells were infected with pBabe-puro or pBabe-puro-GATA3, selected with puromycin for 2 to 5 days, and analyzed by Q-RT-PCR. Data are
expressed relative to the corresponding values for vector-infected cells as mean ± SD from triplicates of a representative experiment.
(F) MCF-10A cells infected with pBabe-puro-empty or pBabe-puro-GATA3 were pulse-labeled with BrdU. Cells were stained with anti-BrdU antibody and PI and
subjected to flow cytometry. BrdU-positive cells are marked by the box and the percentage of BrdU-positive cells are shown.
(G) GATA3 binds to p18 locus. The upper panel illustrates the human p18 locus, which expresses multiple transcripts, including a longer 2.4 kb transcript from an
upstream promoter and a shorter 1.2 kb transcript from a downstream promoter. A 40 bp region containing 10 GATA sequences in tandem is shown. The dotted
line represents the 8.9 kb region screened for GATA3 binding by ChIP assay using 33 pairs of primers. Locations and results of representative amplicons are
shown, MCF-7 cells were used for this assay.
(H) Working model for the function and mechanism of GATA3 and INK4c in regulating mammary stem, progenitor, and luminal cell differentiation.recent evidence thatGata3 is a highly enriched transcription factor
in the mammary epithelium of pubertal mice and plays a critical
role in luminal cell differentiation (Asselin-Labat et al., 2007;
Kouros-Mehr et al., 2006), we hypothesized that p18 might be
a downstream target of GATA3 in controlling luminal cell prolifer-
ation and differentiation. We first examined the expression of
Gata3 and p18 in different populations of mammary epithelium.
Sorted luminal progenitor enriched C24+CD29 cells from WT
mice at a pubertal age (Shackleton et al., 2006) expressed
12-fold more Gata3 than C24CD29 cells that include basal/
myoepithelial cells and other cell types (Figure 7A), confirming
thatGata3 ispredominantly expressed in luminal epithelium. Inter-
estingly, the Gata3 mRNA level in MaSC-enriched C24+CD29+
cells was also much higher than in C24CD29 cells, suggesting
a potential, and yet to be defined, function of Gata3 in MaSCs.
Again, we observed that the p18 mRNA level was inversely corre-398 Cancer Cell 15, 389–401, May 5, 2009 ª2009 Elsevier Inc.lated withGata3; it was significantly lower in both MaSC-enriched
C24+CD29+ and luminal progenitor enriched C24+CD29 cells
than in C24CD29 cells (Figure 7A).
To directly determine whether Gata3 negatively regulates p18
in mammary epithelium, we first determined the p18 protein level
in Gata3-deficient mouse mammary tissue. Specific deletion/
reduction ofGata3 in the mammary gland was achieved by preg-
nancy of Gata3f/f;WAP-cre dams and resulted in a robust
increase of p18 protein (Figure 7B). Likewise, the knocking
down of GATA3 expression in human MCF-7 and 293T cells by
two different siRNA oligonucleotide duplexes resulted in
increased p18 mRNA and protein levels (Figures 7C and 7D).
Conversely, overexpression of GATA3 in MCF-10A cells inhibited
p18 mRNA expression (Figure 7E) and increased cell prolifera-
tion, as determined by BrdU incorporation (Figure 7F). We also
examined Gata3 expression both in vivo in animals at different
Cancer Cell
A Mouse Model for ER+ Luminal Breast Cancerages and in vitro in acini-cultured in 3D Matrigel using mammary
cells. Gata3 expression was readily detected, but no discernible
difference in Gata3 expression was detected between WT and
p18/ mammary epithelial cells (data not shown).
Examination of the p18 promoter reveals several GATA3
consensus sites, including a 40-bp region containing ten
GATA3 sequences in tandem located 5.3 kb upstream of the
translational initiation ATG codon (Figure 7G). To determine if
GATA3 directly binds to the p18 locus, we analyzed 6.6 kb
upstream and 2.3 kb downstream of the start codon of the
human p18 gene by chromatin-immunoprecipitation (ChIP)
assay using 33 pairs of primers. Six of 33 amplicons, four
upstream (a, b, c, and d in Figure 7G) and two downstream of
the start codon (h and i in Figure 7G), were specifically enriched
in the GATA3 immunoprecipitation (Figure 7G). Except for
amplicon h, all positive amplicons contain at least one putative
GATA3 binding site (data not shown), including one that contains
ten GATA3 repeats. Together, these results demonstrate that
GATA3 binds to the p18 gene and negatively regulates its
transcription.
DISCUSSION
Balb/c-p18 Mouse as a Model for ER+ Luminal Tumors
In this study, we report that nearly 90% of female p18-null mice in
the Balb/c background spontaneously developed mammary
tumors with a median tumor-free survival time of 14 months.
To the best of our knowledge, Balb/c-p18 mice develop
mammary tumors at the highest rate among all mutant mice
with germline mutations. Our findings support the rate-limiting
function of INK4-cyclin Ds-CDK4/6 in suppressing mammary
tumorigenesis.
The results presented here also suggest the existence of
a genetic modifier(s) in Balb/c mice that interacts with p18 defi-
ciency epistatically to promote tumorigenesis. The possibility of
p16Ink4a, a tumor suppressor that sustained two allelic variations
in Balb/c affecting its inhibitory function toward CDK4 (Zhang
et al., 1998), has been ruled out by our observation that p16/;
p18/ in CJ57BL/6 background did not develop mammary
tumor at an elevated rate (Ramsey et al., 2007). Identifying
the modifier(s) remains a daunting challenge, especially when
considering multiple modifiers could have contributed to the
tumor susceptibility phenotype in Balb/c.
The mammary tumors developed in Balb/c-p18 mice are
predominantly luminal. In addition to data presented here,
gene expression profiling analysis clustered most tumors
derived from p18/ mice with other mice known to have luminal
mammary tumors (e.g., MMTV-Neu and MMTV-PyMT) and
showed expression of the XBP1 cluster (unpublished results).
Our studies demonstrate that loss of p18 selectively stimulates
mammary luminal progenitor cell proliferation at an early age
and maintains them at a hyperproliferative state throughout
life, leading to increased and sustained proliferation of luminal
epithelial cells and eventual development of luminal tumors.
Furthermore, the mammary tumors developed in p18/ mice
are ER positive. These features establish the Balb/c-p18 mouse
as an animal model for elucidating the molecular mechanism
and cell origin of luminal breast cancers and for preclinical
studies of treatment for ER-positive luminal tumors.Control of Luminal Cell Differentiation by GATA3
and p18
GATA3 is expressed early during embryogenesis and specifically
in both ductal and alveolar luminal epithelial cells. Genetic anal-
yses have recently demonstrated that Gata3 plays multiple
morphological and functional roles in mammary development,
including terminal end bud, placode and nipple formation, ductal
elongation and invasion, and subsequent lactation (Asselin-
Labat et al., 2007; Kouros-Mehr et al., 2006). Blockage of luminal
progenitor cells to differentiate was recognized as the most likely
cellular basis underlying these various functions; the luminal
progenitor pool was increased with a concurrent decrease of
differentiated luminal cells in MMTV–Cre;Gata3f/f mice, whereas
ectopic expression of Gata3 in MaSC-enriched cells promoted
the stem cells to differentiate along the alveolar cell lineage.
Loss ofp18 resulted in expansion of luminal progenitor cells, sug-
gesting that p18 functions to either restrict stem cells from asym-
metric divisions and produce luminal progenitors or to maintain
luminal progenitors at a quiescent state (Figure 7H). We further
suggest that GATA3 promotes the differentiation of mammary
stem cells along the luminal lineage through a network of tran-
scription regulation that, on one hand, represses p18 expression
to allow the expansion of either luminal progenitors or transit cells
of luminal lineage and, on the other hand, activates the expres-
sion of genes such as FOXA1 and ERa to induce and maintain
the differentiation of mature luminal cells. Further investigations
are necessary to determine the factor that trans-activates and/
or maintains p18 expression in luminal progenitors.
Loss of Gata3 would result in an accumulation of p18 in the
luminal progenitor cells, blocking them from entering an active
cell cycle and undergoing subsequent differentiation. Loss of
p18, although stimulating the proliferation of luminal progenitor
cells and initiating luminal tumorigenesis, would not significantly
impair the differentiation of luminal lineage in the presence of
normal GATA3 function. Our study also provides a plausible
molecular explanation underlying the pathological association
and prognostic feature of GATA3. A high level of GATA3, which
has been associated with less aggressive lower-grade cancers
(Mehra et al., 2005; Sorlie et al., 2003; van de Rijn et al., 2002),
would suppress p18 expression, and a decreased p18 level
would favor the development of luminal type breast cancers
that have a better outcome for patients.
p18 and p16 May Collaboratively Constrain Stem
and Progenitor Cell Proliferation
Genetic studies have recently linked the function of p16 with the
control of stem and progenitor cells during aging in neuronal,
hematopoietic, and pancreatic lineages (Janzen et al., 2006;
Krishnamurthy et al., 2006; Molofsky et al., 2006). These genetic
analyses, combined with three lines of evidence from biochem-
ical properties, structural analyses, and the patterns of gene
expression, support a model that p16 and p18 collaboratively
control stem and progenitor cell cycles. First, rapid turnover of
the p21 family of CDK inhibitors and intrinsic stability of INK4
proteins make p21 and INK4 family proteins more suitable for
inducing and maintaining a transient and stable cell cycle arrest,
respectively. Second, individual INK4 proteins bind to CDK4 and
CDK6 with similar affinity. As a result, the activity of CDK4/6 in
a given cell is determined by the total concentration of all INK4Cancer Cell 15, 389–401, May 5, 2009 ª2009 Elsevier Inc. 399
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related and collaborative. Third, p18 is expressed early and
sustains a high level throughout life in many adult tissues,
whereas the expression of p16 is undetectable in young tissues
and is induced during aging (Krishnamurthy et al., 2004; Zindy
et al., 1997). These observations led us to propose that p18
and p16 collaboratively constrain stem cell self-renewal and
progenitor cell proliferation, with p18 playing a major role in
maintaining the homeostasis of stem/progenitor cells from early
embryogenesis throughout adulthood and p16 in limiting stem/
progenitor cell function during aging.
EXPERIMENTAL PROCEDURES
Mice, Histopathology, and Immunohistochemistry
The generation and genotyping of p18 and floxed Gata3 mice have been
described previously (Franklin et al., 1998; Pai et al., 2003). p18 mutant mice in
BL/6 background were backcrossed for seven generations with BALB/c mice
before used for this study as Balb/c-p18 mutant mice. Tissues of most organs
were removed, fixed in 10% neutral buffered formalin, and examined histologi-
cally by two pathologists after H&E staining. Immunohistochemistry and primary
antibodies were as described previously (Bai et al., 2003). The IACUC (Institu-
tional Animal Care and Use Committee) at UNC approved all procedures.
Morphologic Characterization of Mammary Epithelium
To examine and quantify small light cell (SLC), undifferentiated large light cell
(ULLC), differentiated large light cell (DLLC), large dark cell (LDC), and myoepi-
thelial cell (MYO), we followed criteria defined by Smith and colleagues (Chepko
et al., 2005; Smith and Medina, 1988). Cells that could not be clearly defined
were categorized as unknown (UK). Three pairs of WT or p18/ mice at 2 to
3 months of age were dissected and stained with H&E. All sections were read
by two different pathologists (X-H.P. and F.B.). Only sections containing large
amounts of epithelium of sufficient quality for counting were selected. Epithelial
structures were classified as ducts when they were singular elements associ-
ated with no other epithelial structures. They were classified as lobules if they
appeared clustered with other small, round epithelial structures or if there
were small, round structures that budded from a larger, longitudinally sectioned
duct. Cells in terminal end buds were also included in the lobule count.
In Vivo BrdU Labeling Assay
For short-term in vivo BrdU labeling analysis, mice were injected with 1 ml per
100 g body weight BrdU cell proliferation labeling reagent (Amersham Biosci-
ence, Little Chalfond, UK) 1 hr before they were killed. Tissues were immuno-
stained with anti-BrdU antibody (Abcam, Cambridge, MA). To determine label
retaining cells (LRCs), littermate mice at 1 month of age were injected intraper-
itoneally with BrdU (50 mg/kg) twice a day for 7 consecutive days followed by
chase for 1 day or 37 days before death. Four-micrometer mammary sections
were immunostained with antibodies against BrdU, CK5, and CK8. When
counting LRCs, only sections containing a large amount of mammary epithe-
lium of sufficient quality were selected, and only confirmed BrdU-positive cells
in the duct were counted. Parallel staining of the serial sections for CK8, BrdU,
and DAPI was performed to calculate the percentage of CK8+BrdU+ cells in
DAPI+ mammary epithelium.
Four mammary glands (the fourth and fifth pairs) from each mouse were
examined, and at least 600 cells per mammary (more than 2400 epithelial cells
per mouse) were counted in the parallel staining of serial sections. The average
percentages of BrdU+ cells were calculated from three WT and three p18-null
mice, respectively.
Patients and Gene-Expression Data Set and Statistical Analyses
We used a data set of breast cancer samples from 295 women (van de Vijver
et al., 2002). Patients were dichotomized into two groups as above or below
median for each gene’s expression value (2 based log ratio of red channel
intensity and green channel intensity). Kaplan-Meier survival plots were per-
formed for relapse-free survival and Overall survival. Cox-Mantel log-rank
tests were applied to compare the survival differences and obtained p values,400 Cancer Cell 15, 389–401, May 5, 2009 ª2009 Elsevier Inc.using WinSTAT for Excel (R. Fitch Software). We then compared the two
groups of patients for each gene versus five breast cancer subtypes (Hu
et al., 2006; Sorlie et al., 2003) using two-way contingency-table analyses
and SAS software (Cary, NC). All of the statistical analyses were performed
with StatsDirect 2.4.3 software (StatsDirect Statistical Software). The survival
rate was calculated by the Kaplan-Meier method.
Detailed descriptions for the mammary cell preparation, FACS analysis, cell
sorting, 3D Matrigel assay, colony-formation assay, mammosphere assay, cell
culture, retroviral infection, RNA interference, western blot, quantitative real-
time polymerase chain reaction, and ChIP assay are available in Supplemental
Experimental Procedures.
SUPPLEMENTAL DATA
The Supplemental Data include five figures, two tables, and Supplemental
Experimental Procedures and can be found with this article online at http://
www.cell.com/cancer-cell/supplemental/S1535-6108(09)00079-8.
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